{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-000112","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.573664+00:00","generated_at":"2026-06-20T11:35:42.763682+00:00","sec_items":["7.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexaria Bioscience hires former GW Pharma USA President Julian Gangolli as Strategic Advisor","bullets":["Julian Gangolli, former President of GW Pharmaceuticals USA, appointed as Strategic Advisor.","He oversaw FDA approval of Epidiolex, the first pure CBD drug, leading to GW's $7.2B acquisition by Jazz.","Previously a senior Allergan executive; part of management that sold Allergan to Actavis in 2015.","Granted 5,000 stock options at $2.73 per share, exercisable for 5 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-000112","json":"https://secwatch.observer/filing/0001640334-23-000112.json","markdown":"https://secwatch.observer/filing/0001640334-23-000112.md","text":"https://secwatch.observer/filing/0001640334-23-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000112/0001640334-23-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000112/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:35:42.763682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}